This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

NCT05480293 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

446

Enrollment

INDUSTRY

Sponsor class

Conditions

Wet Age-related Macular Degeneration

Interventions

DRUG: Ranibizumab
DRUG: SCT510A

Sponsor

Sinocelltech Ltd.